Abstract
BACKGROUND: Pancreatic cancer (PC) remains a highly aggressive disease with a poor postoperative 5-year survival of around 25%, attributable to its immunosuppressive and fibrotic tumor microenvironment. Prognostic models that combine immune checkpoint markers with fibrotic features are still needed. METHODS: We analyzed qualifying surgically resected PC specimens. Immunohistochemistry was used to evaluate PD-L1, CTLA-4, and α-SMA expression. Extracellular matrix volume (ECV) at the tumor center (ECVC) and peritumoral region (ECVP) was measured by three radiologists using single-energy CT. Collagen fraction (CF) was assessed via Masson's trichrome staining. Multivariate Cox regression identified independent predictors of overall survival (OS); a prognostic nomogram was then developed. RESULTS: Among 268 enrolled patients, divided into training (n=215) and validation (n=53) sets via Five-fold cross-validation, PD-L1 expression correlated positively with α-SMA, T stage, and N stage. Multivariate analysis identified α-SMA H-score, Masson-CF, ECVC, ECVP, T stage, N stage, CA19-9, neutrophil-to-lymphocyte ratio (NLR), vascular invasion, and chemotherapy as independent OS predictors. The nomogram integrating these factors outperformed TNM staging in predicting OS. CONCLUSION: High PD-L1 expression is associated with enhanced fibrosis, greater tumor burden, and nodal metastasis in PC. Patients exhibiting elevated PD-L1 levels, significant fibrotic burden, advanced T or N stage, or increased NLR demonstrate reduced OS. The developed nomogram enhances individualized prediction of OS. These findings support the hypothesis that combining immune checkpoint blockade, TGF-β inhibition, and chemotherapy may represent a promising therapeutic strategy for PC patients with high PD-L1 expression and pronounced fibrosis.